Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231205023 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Daniel Tobben und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UNC Health Rex, Raleigh, NC, USA. Hauptthemen laut MEDLINE: Naltrexone, Critical Illness, Polyethylene Glycols, Narcotic Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Background
Constipation impacts 58% to 83% of critically ill patients and is associated with increased time on mechanical ventilation, delirium, and increased length of stay (LOS) in the intensive care unit (ICU).
Objective
The purpose of this study was to evaluate the efficacy of enteral naloxegol (NGL) versus subcutaneous methylnaltrexone (MNTX) for the management of opioid-induced constipation (OIC) in critically ill patients.
Methods
A retrospective analysis was conducted on adult patients admitted to the ICU who received a parenteral opioid infusion for at least 4 hours and experienced no bowel movement (BM) within the 48-hour period preceding the administration of NGL or MNTX. The primary outcome was time to first BM from the start of NGL or MNTX therapy. Secondary outcomes included number of BMs 72 hours following NGL or MNTX administration, ICU LOS, and cost-effectiveness.
Results
After exclusion criteria were applied, 110 and 51 patients were included in the NGL and MNTX groups, respectively. With a 10% noninferiority margin, NGL was noninferior to MNTX (Wald statistic = 1.67; P = 0.047). Median time to first BM was 23.7 hours for NGL and 18.3 hours for MNTX patients. Median LOS was 14 days (NGL) and 12 days (MNTX), and the average number of BMs in 72 hours was 3.9 for NGL and 3.8 for MNTX. Using wholesale acquisition cost (WAC), the cost per BM for NGL and MNTX was $21.74 and $170.00, respectively. Conclusion and relevance: This study determined that NGL and MNTX had similar time to BM. NGL appears to be a safe and effective alternative with cost-saving potential in treating OIC in critically ill patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, UNC Health Rex, Raleigh, NC, USA.
- UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
ORCID-Profile: Daniel Tobben, Tramaine Young
Zitieren
APA
Tobben, D., Carpenter, S., Kolar, R., Merritt, T., Young, T., Hauser, P., & Collier, T. (2024). Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231205023
Vancouver
Tobben D, Carpenter S, Kolar R, Merritt T, Young T, Hauser P, et al. Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231205023
BibTeX
@article{Tobben2024,
author = {Tobben, Daniel and Carpenter, Sheniece and Kolar, Rachel and Merritt, Tyler and Young, Tramaine and Hauser, Paloma and Collier, Tia},
title = {Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231205023}
}
EUVIMED